Arthrogryposis Market Report 2026

The arthrogryposis market size has grown strongly in recent years. It will grow from $0.98 billion in 2025 to $1.04 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to improved clinical understanding of congenital disorders, expansion of pediatric orthopedic care, increased availability of rehabilitation services, adoption of physical therapy interventions, growth of specialized treatment centers.

The arthrogryposis market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing investments in rare disease research, rising demand for personalized rehabilitation programs, expansion of early screening initiatives, growing focus on long-term quality of life improvement, increasing integration of advanced diagnostic technologies. Major trends in the forecast period include increasing focus on early diagnosis and intervention, rising adoption of multidisciplinary treatment approaches, growing use of advanced imaging diagnostics, expansion of long-term rehabilitation programs, enhanced supportive care strategies.

The increasing prevalence of congenital disorders is anticipated to drive the growth of the arthrogryposis market in the coming years. Congenital disorders are structural or functional abnormalities that develop during fetal growth and are present at birth. The rising occurrence of congenital disorders is linked to factors such as advancements in prenatal diagnostics, environmental exposures, genetic mutations, and lifestyle changes. Arthrogryposis aids in understanding congenital disorders by emphasizing the impact of fetal movement, genetic influences, and neuromuscular development on musculoskeletal abnormalities. For example, in February 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 240,000 newborns worldwide die from congenital disorders within the first 28 days of life each year. Moreover, congenital conditions are responsible for an estimated 170,000 child deaths between the ages of 1 month and 5 years. Consequently, the growing prevalence of congenital disorders is fueling expansion in the arthrogryposis market.

The growth of telehealth services is expected to drive the expansion of the arthrogryposis market in the coming years. Telehealth services involve the use of digital communication technologies, such as video calls, phone calls, and online messaging, to deliver healthcare services and consultations remotely, allowing patients to access medical care from home or other locations. The adoption of telehealth services is increasing due to their convenience, accessibility, and ability to lower healthcare costs while enhancing patient access to care, particularly in remote or underserved regions. Arthrogryposis benefits from telehealth services by facilitating remote consultations, early diagnosis, and ongoing management of joint contractures, improving access to specialized care for patients with mobility limitations. For example, in May 2024, according to the Australian Digital Health Agency, an Australia-based government organization, over 95,000 practitioners had used telehealth services, and 118.2 million telehealth services were provided to 18 million patients over the past two years. As a result, the growth of telehealth services is contributing to the expansion of the arthrogryposis market.

Major companies in the arthrogryposis treatment market are concentrating on developing advanced orthopedic solutions, such as guided-growth systems, to improve deformity correction, minimize surgical burden, and promote better functional outcomes in patients. Guided-growth systems allow controlled modulation of bone alignment during a child’s growth, enabling clinicians to gradually correct joint contractures with minimal tissue disruption. For example, in June 2023, OrthoPediatrics Corp., a US-based pediatric orthopedic company, introduced a growth modulation system with guided implant technology that offers precise intraoperative alignment control, minimally invasive implantation, patient-specific sizing options, compatibility with standard surgical instruments, and enhanced monitoring of growth progression. Designed to facilitate targeted deformity correction, this technology provides clinicians with a more controlled and less invasive method for managing joint abnormalities commonly observed in arthrogryposis.

Major companies operating in the arthrogryposis market are Boston Children’s Hospital, Seattle Children’s Hospital, Shriners Hospitals for Children, Texas Scottish Rite Hospital for Children, Gillette Children’s Specialty Healthcare, Cleveland Clinic, Johns Hopkins Hospital, Mayo Clinic, Children’s Hospital of Philadelphia, Nationwide Children’s Hospital, Children’s Healthcare of Atlanta, Nemours Children’s Health, Phoenix Children’s Hospital, Cincinnati Children’s Hospital Medical Center, St Jude Children’s Research Hospital, Rady Children’s Hospital San Diego, Children’s National Hospital, Great Ormond Street Hospital, SickKids Hospital Toronto, Royal Children’s Hospital Melbourne.

North America was the largest region in the arthrogryposis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arthrogryposis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arthrogryposis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the arthrogryposis market by increasing costs of imported diagnostic imaging equipment, orthopedic devices, rehabilitation tools, and surgical instruments used in treatment and management. Pediatric care centers and hospitals in North America and Europe are most affected due to dependence on imported medical equipment, while Asia-Pacific faces cost pressures in specialized device procurement. These tariffs are increasing treatment expenses and delaying equipment upgrades. However, they are also supporting domestic production of orthopedic devices and strengthening regional rehabilitation equipment supply chains.

The arthrogryposis market research report is one of a series of new reports that provides arthrogryposis market statistics, including arthrogryposis industry global market size, regional shares, competitors with a arthrogryposis market share, detailed arthrogryposis market segments, market trends and opportunities, and any further data you may need to thrive in the arthrogryposis industry. This arthrogryposis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arthrogryposis describes a collection of congenital conditions marked by multiple joint contractures, causing stiffness and restricted movement. It develops due to decreased fetal movement in the womb, which may arise from neurological, muscular, or connective tissue disorders.

The main types of arthrogryposis include classic arthrogryposis, distal arthrogryposis, and amyoplasia. Classic arthrogryposis is a condition marked by multiple joint contractures (stiffness or fixation) present at birth, often accompanied by muscle weakness and restricted mobility. Treatment includes occupational therapy, physical therapy, surgery, imaging diagnostics, and CT scans. The disorder can affect children, adults, and the elderly, and treatment is made available through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks.

The arthrogryposis market consists of revenues earned by entities by providing services such as medical diagnosis and consultation, surgical interventions, orthotic services, and pediatric care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.